PORTLAND, OR - SWOG Cancer Research Network members will share results of five network-led studies at the San Antonio Breast Cancer Symposium, or SABCS, an international gathering of breast cancer physicians and researchers expected to draw 8,000 virtual attendees from more than 80 countries that runs Dec. 8-11.
One trial led by SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will be the focus of a press conference to be held Tuesday, Dec. 8 at 12 noon Central Time. Kevin Kalinsky, MD, a long-time SWOG investigator and director of the Glenn Family Breast Center at the Winship Cancer Institute of Emory University, will present findings from S1007, a trial known as RxPONDER. SWOG, the NCI, and the American Association for Cancer Research, a sponsor of SABCS, will release details of those findings after the press event.
"There is a lot for SWOG to celebrate about the work we're sharing," said Lajos Pusztai, MD, PhD, chair of SWOG's breast cancer committee and professor of medicine at Yale University and director of Breast Cancer Translational Research and co-director of the Cancer Center Genomics, Genetics, and Epigenetics program at Yale Cancer Center. "All of our SABCS results will advance breast cancer science and medicine, and one will change practice."
Here are summaries of other presentations on SWOG trials at the symposium:
###
Stecklein's work was funded by the National Cancer Institute through grants CA180888 and CA180819, and in part by Amgen.
Henry's work was funded by the National Cancer Institute through grant CA189974 and in part by The Hope Foundation for Cancer Research.
Paoletti's work was funded by the National Cancer Institute through grants CA180888, CA180819, CA196175; and in part by AstraZeneca. Biovica funded the TK1 testing.
Park's work was funded by the National Cancer Institute through grant CA180888.
SWOG Cancer Research Network is part of the National Cancer Institute's National Clinical Trials Network and the NCI Community Oncology Research Program, and is part of the oldest and largest publicly-funded cancer research network in the nation. SWOG has nearly 12,000 members in 47 states and six foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org.